A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.